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background:  A novel necrosis inhibitor, NecX, inhibits necrosis which is the main pathophysiology of ischemia-reperfusion (I/R) injury, through 
blocking of the opening of mitochondrial permeability transition pore.
methods: H9C2 cardiomyoblasts was exposed to hypoxia-reoxygenation injury after pretreatment with dimethyl sulfoxide, NecX, vitamin C, a 
combination of vitamin C and E, N-acetylcysteine or an apoptosis inhibitor (Z-VAD-fmk). We analyzed the mechanisms of cell death, mitochondrial 
membrane potential and mitochondrial Ca2+ level. Using rats exposed to myocardial ischemia followed by reperfusion, we investigated the efficacy 
of NecX.
results: NecX had potent scavenging activity on reactive oxygen species (ROS) as well as inhibitory effect on a ROS-generating enzyme. NecX 
treated H9C2 rat cardiomyoblasts had fewer necrotic cells and more viable cells than other-treated cells. NecX maintained higher mitochondrial 
membrane potential and prevented Ca2+ overload. Pretreatment with NecX markedly inhibited myocardial necrosis (NecX, 7.8±7.8%; control, 
65.4±2.4%, P=0.017; CsA, 32.3±5.1%, P=0.041) and reduced the area of fibrosis (NecX, 4.8±0.9%; control, 25.7±1.6%, P=0.011; CsA, 18.8±1.3%, 
P=0.006). Additionally, it preserved systolic function and prevented pathologic dilatory remodeling of left ventricle.
Conclusions: NecX prevented cell necrosis in vitro and reduced myocardial infarct size and preserved heart function in vivo I/R injury model.
 
